Overview

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

This study is for subjects with untreated Stage IV small cell lung cancer. Subjects will be given radiation therapy for five days, followed by standard of care chemo-immunotherapy (etoposide + carboplatin or cisplatin + durvalumab) for 4 cycles. Subjects may continue to receive durvalumab after 4 cycles have been completed until disease progression.

Phase:

Phase 2

Details

Lead Sponsor:

Weill Medical College of Cornell University

Treatments:

Carboplatin
Durvalumab
Etoposide